TVRD Data Readout: a positive outcome, +22.8%

On June 24, 2024, TTI-101 — Tvardi Therapeutics, Inc. (Hepatocellular Carcinoma) reached its Data Readout. The result was a positive outcome, and the stock moved +22.8% in the window around the event. It had already run -58.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.